ARAV Archives - BioTuesdays

Markets

Cantor cuts Aravive to neutral; PT to 25 cents on pipeline setback

Cantor Fitzgerald downgraded Aravive (NASDAQ:ARAV) to “neutral” from “overweight” and slashed its price target to 25 cents from $18 after the company indicated it might be forced to cease operations. The stock closed at...

August 22, 2023

Developments

Aravive flunks Phase 3 in platinum-resistant ovarian cancer

Aravive’s (NASDAQ:ARAV) Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre...

August 3, 2023

Markets

HCW ups Aravive PT on higher probability of success for batiraxcept

H.C. Wainwright raised its price target for Aravive (NASDAQ:ARAV) to $12 from $7 after increasing its probability of success for batiraxcept to 55% from 35% for platinum-resistant ovarian cancer (PROC) “to further value...

March 15, 2023

Developments

FDA grants orphan drug to Aravive’s batiraxcept for pancreatic cancer

The FDA granted orphan drug designation for Aravive’s (NASDAQ:ARAV) batiraxcept for the treatment of pancreatic ductal adenocarcinoma cancer (PDAC). In a statement, Gail McIntyre, Ph.D., DABT, CEO of Aravive, said three...

March 1, 2023

Developments

Aravive to present positive updated data at ASCO GU cancer symposium

Aravive (NASDAQ:ARAV) will present updated results from its ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU)...

February 14, 2023

Developments

Aravive completes enrolment in Phase 3 ovarian cancer trial

Aravive (NASDAQ:ARAV) achieved full enrollment in a global registrational Phase 3 trial of batiraxcept plus paclitaxel for platinum-resistant ovarian cancer (PROC). The Phase 3 AXLerate-OC trial is evaluating efficacy...

January 4, 2023

Developments

FDA grants fast tract to Aravive’s batiraxcept for ccRCC

The FDA granted fast track designation to Aravive’s (NASDAQ:ARAV) lead program, batiraxcept, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have progressed after...

November 29, 2022

Developments

Aravive posts positive updated Phase 1b data in clear cell renal cell carcinoma

Aravive (NASDAQ:ARAV) reported positive new data from the Phase 1b portion of an ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer (ccRCC) and new data from a biomarker high subgroup. Key findings...

March 3, 2022

Developments

Aravive doses first patient in Phase 2 clear cell renal cell carcinoma trial

Aravive (NASDAQ:ARAV) dosed the first patient in the Phase 2 portion of a Phase 1b/2 study of batiraxcept for the treatment of clear cell renal cell carcinoma (ccRCC). “Safety and preliminary activity data...

January 31, 2022

Feature

Aravive developing targeted cancer therapeutics to treat metastatic disease

Aravive (NASDAQ:ARAV) is taking a differentiated approach with its lead molecule, batiraxcept, to target inhibition of the GAS6/AXL signaling pathway in several cancer indications.

January 25, 2022

Tag - ARAV

Cantor cuts Aravive to neutral; PT to 25 cents on pipeline setback

Aravive flunks Phase 3 in platinum-resistant ovarian cancer

HCW ups Aravive PT on higher probability of success for batiraxcept

FDA grants orphan drug to Aravive’s batiraxcept for pancreatic cancer

Aravive to present positive updated data at ASCO GU cancer symposium

Aravive completes enrolment in Phase 3 ovarian cancer trial

FDA grants fast tract to Aravive’s batiraxcept for ccRCC

Aravive posts positive updated Phase 1b data in clear cell renal cell carcinoma

Aravive doses first patient in Phase 2 clear cell renal cell carcinoma trial

Aravive developing targeted cancer therapeutics to treat metastatic disease

General

More